Panagora Asset Management’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-351
| Closed | -$90K | – | 2147 |
|
|
2021
Q2 | $90K | Hold |
351
| – | – | ﹤0.01% | 1928 |
|
|
2021
Q1 | $105K | Buy |
+351
| New | +$109K | ﹤0.01% | 1994 |
|
|
2020
Q3 | – | Sell |
-712
| Closed | -$247K | – | 2734 |
|
|
2020
Q2 | $247K | Buy |
712
+460
| +183% | +$144K | ﹤0.01% | 1459 |
|
|
2020
Q1 | $68K | Sell |
252
-216
| -46% | -$66.8K | ﹤0.01% | 1812 |
|
|
2019
Q4 | $151K | Sell |
468
-299
| -39% | -$86.7K | ﹤0.01% | 1696 |
|
|
2019
Q3 | $209K | Sell |
767
-12,466
| -94% | -$4.57M | ﹤0.01% | 1615 |
|
|
2019
Q2 | $7.06M | Sell |
13,233
-838
| -6% | -$420K | 0.03% | 415 |
|
|
2019
Q1 | $7.09M | Buy |
14,071
+9,327
| +197% | +$5.53M | 0.03% | 425 |
|
|
2018
Q4 | $2.34M | Sell |
4,744
-3,438
| -42% | -$2.08M | 0.01% | 723 |
|
|
2018
Q3 | $7.48M | Buy |
8,182
+1,115
| +16% | +$952K | 0.03% | 423 |
|
|
2018
Q2 | $5.18M | Sell |
7,067
-17,022
| -71% | -$19.6M | 0.02% | 514 |
|
|
2018
Q1 | $38.4M | Sell |
24,089
-18,327
| -43% | -$23.6M | 0.15% | 144 |
|
|
2017
Q4 | $38M | Sell |
42,416
-13,167
| -24% | -$7.79M | 0.14% | 160 |
|
|
2017
Q3 | $20M | Sell |
55,583
-1,747
| -3% | -$546K | 0.08% | 247 |
|
|
2017
Q2 | $16.8M | Sell |
57,330
-19,893
| -26% | -$5.75M | 0.07% | 283 |
|
|
2017
Q1 | $27.2M | Buy |
77,223
+4,882
| +7% | +$1.1M | 0.11% | 199 |
|
|
2016
Q4 | $13.3M | Buy |
72,341
+8,289
| +13% | +$1.69M | 0.06% | 315 |
|
|
2016
Q3 | $16.5M | Sell |
64,052
-25,079
| -28% | -$6.46M | 0.08% | 259 |
|
|
2016
Q2 | $19M | Buy |
89,131
+416
| +0.5% | +$93K | 0.09% | 220 |
|
|
2016
Q1 | $18.3M | Sell |
88,715
-1,663
| -2% | -$319K | 0.09% | 228 |
|
|
2015
Q4 | $22.8M | Buy |
90,378
+3,784
| +4% | +$778K | 0.11% | 191 |
|
|
2015
Q3 | $14.2M | Sell |
86,594
-3,688
| -4% | -$652K | 0.08% | 269 |
|
|
2015
Q2 | $16.9M | Buy |
90,282
+16,992
| +23% | +$2.92M | 0.08% | 253 |
|
|
2015
Q1 | $12.1M | Buy |
73,290
+9,297
| +15% | +$1.91M | 0.06% | 301 |
|
|
2014
Q4 | $14.9M | Buy |
63,993
+6,138
| +11% | +$1.31M | 0.08% | 253 |
|
|
2014
Q3 | $10.5M | Buy |
57,855
+1,406
| +2% | +$269K | 0.05% | 329 |
|
|
2014
Q2 | $10.9M | Sell |
56,449
-3,161
| -5% | -$559K | 0.05% | 327 |
|
|
2014
Q1 | $10.8M | Buy |
59,610
+1,635
| +3% | +$324K | 0.05% | 338 |
|
|
2013
Q4 | $9.87M | Buy |
57,975
+569
| +1% | +$91.8K | 0.05% | 373 |
|
|
2013
Q3 | $9M | Sell |
57,406
-2,958
| -5% | -$547K | 0.04% | 365 |
|
|
2013
Q2 | $10.5M | Buy |
+60,364
| New | +$9.26M | 0.05% | 294 |
|
Other funds holding NKTR
MC
BG
Panagora Asset Management's NKTR Position: Q3 2021 in Review
Panagora Asset Management sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 351 shares — an estimated $90K sold.
Panagora Asset Management first reported a position in NKTR in Q2 2013 and held it in 31 quarters. The position peaked at $38.4M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.
- Panagora Asset Management reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
- Panagora Asset Management sold 351 Nektar Therapeutics shares in Q3 2021, an estimated $90K.
- Panagora Asset Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 31 quarters.
- Panagora Asset Management's Nektar Therapeutics position peaked at $38.4M in Q1 2018.
- 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.
Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.